Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

Erste Group analyst Hans Engel upgraded Amgen (AMGN) to Buy from Hold. Amgen has a higher operating margin and a higher return on equity than ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Much like the straightened origins of Apple or Microsoft, Amgen combined a relaxed attitude with determination and flexibility in dealing with limited resources. The CEO’s office was housed in a ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen has been a biotechnology pioneer since ... AM: Clinical trials can be limited in the number of patients involved and thus their ability to detect potential rare safety events that may ...

While downside risk potential still exists, the overall risk-reward is in a better place, although there is limited incentive for biotech-focused investors to rotate into Amgen now. Granted ...

Amgen Inc (NASDAQ: AMGN) reported better-than-expected fourth-quarter results on Tuesday, but its shares fell 2.5% in ...